202 related articles for article (PubMed ID: 32936431)
21. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
22. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
23. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions.
Jaumot M; Hancock JF
Oncogene; 2001 Jul; 20(30):3949-58. PubMed ID: 11494123
[TBL] [Abstract][Full Text] [Related]
24. Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Fukuda K; Kawata S; Tamura S; Matsuda Y; Inui Y; Igura T; Inoue S; Kudara T; Matsuzawa Y
Hepatology; 1998 Sep; 28(3):796-804. PubMed ID: 9731575
[TBL] [Abstract][Full Text] [Related]
25. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
26. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
27. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
28. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
[TBL] [Abstract][Full Text] [Related]
29. GTP-binding proteins as oncogenes in human tumors.
McCormick F
Environ Health Perspect; 1991 Jun; 93():17-8. PubMed ID: 1773789
[No Abstract] [Full Text] [Related]
30. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells.
Oliveira CJ; Schindler F; Ventura AM; Morais MS; Arai RJ; Debbas V; Stern A; Monteiro HP
Free Radic Biol Med; 2003 Aug; 35(4):381-96. PubMed ID: 12899940
[TBL] [Abstract][Full Text] [Related]
33. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.
Bunda S; Burrell K; Heir P; Zeng L; Alamsahebpour A; Kano Y; Raught B; Zhang ZY; Zadeh G; Ohh M
Nat Commun; 2015 Nov; 6():8859. PubMed ID: 26617336
[TBL] [Abstract][Full Text] [Related]
35. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
36. Rapid activation of mitogen-activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells.
Rao YP; Buckley DJ; Buckley AR
Cell Growth Differ; 1995 Oct; 6(10):1235-44. PubMed ID: 8845300
[TBL] [Abstract][Full Text] [Related]
37. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
38. NMR
Sharma AK; Lee SJ; Rigby AC; Townson SA
Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
[TBL] [Abstract][Full Text] [Related]
39. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
40. Alterations in the insulin signaling pathway induced by immortalization and H-ras transformation of brown adipocytes.
Valverde AM; Lorenzo M; Teruel T; Benito M
Endocrinology; 1997 Aug; 138(8):3195-206. PubMed ID: 9231768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
